» Articles » PMID: 25162889

Transmission of MERS-coronavirus in Household Contacts

Abstract

Background: Strategies to contain the Middle East respiratory syndrome coronavirus (MERS-CoV) depend on knowledge of the rate of human-to-human transmission, including subclinical infections. A lack of serologic tools has hindered targeted studies of transmission.

Methods: We studied 26 index patients with MERS-CoV infection and their 280 household contacts. The median time from the onset of symptoms in index patients to the latest blood sampling in contact patients was 17.5 days (range, 5 to 216; mean, 34.4). Probable cases of secondary transmission were identified on the basis of reactivity in two reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assays with independent RNA extraction from throat swabs or reactivity on enzyme-linked immunosorbent assay against MERS-CoV S1 antigen, supported by reactivity on recombinant S-protein immunofluorescence and demonstration of neutralization of more than 50% of the infectious virus seed dose on plaque-reduction neutralization testing.

Results: Among the 280 household contacts of the 26 index patients, there were 12 probable cases of secondary transmission (4%; 95% confidence interval, 2 to 7). Of these cases, 7 were identified by means of RT-PCR, all in samples obtained within 14 days after the onset of symptoms in index patients, and 5 were identified by means of serologic analysis, all in samples obtained 13 days or more after symptom onset in index patients. Probable cases of secondary transmission occurred in 6 of 26 clusters (23%). Serologic results in contacts who were sampled 13 days or more after exposure were similar to overall study results for combined RT-PCR and serologic testing.

Conclusions: The rate of secondary transmission among household contacts of patients with MERS-CoV infection has been approximately 5%. Our data provide insight into the rate of subclinical transmission of MERS-CoV in the home.

Citing Articles

Modeling-based design of adaptive control strategy for the effective preparation of 'Disease X'.

Wang H, Zhou W, Wang X, Xiao Y, Tang S, Tang B BMC Med Inform Decis Mak. 2025; 25(1):92.

PMID: 39972382 PMC: 11841272. DOI: 10.1186/s12911-025-02920-0.


Ongoing Evolution of Middle East Respiratory Syndrome Coronavirus, Saudi Arabia, 2023-2024.

Hassan A, Muhlemann B, Al-Subhi T, Rodon J, El-Kafrawy S, Memish Z Emerg Infect Dis. 2024; 31(1):57-65.

PMID: 39641462 PMC: 11682817. DOI: 10.3201/eid3101.241030.


Pairwise Accelerated Failure Time Regression Models for Infectious Disease Transmission in Close-Contact Groups With External Sources of Infection.

Sharker Y, Diallo Z, KhudaBukhsh W, Kenah E Stat Med. 2024; 43(27):5138-5154.

PMID: 39362790 PMC: 11583957. DOI: 10.1002/sim.10226.


Surveillance strategies for SARS-CoV-2 infections through one health approach.

Huang C, Su S, Chen K Heliyon. 2024; 10(17):e37128.

PMID: 39286214 PMC: 11403048. DOI: 10.1016/j.heliyon.2024.e37128.


Mucosal immunity in upper and lower respiratory tract to MERS-CoV.

Shrwani K, Mahallawi W, Mohana A, Algaissi A, Dhayhi N, Sharwani N Front Immunol. 2024; 15:1358885.

PMID: 39281686 PMC: 11392799. DOI: 10.3389/fimmu.2024.1358885.